Rabbit B Cell Select® Drives Clinical
Breakthroughs in Cancer Treatment
ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”)
(NASDAQ: IPA), ImmunoPrecise Antibodies Ltd. (the “Company” or
“IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and
technology company, today proudly announces the clinical progress
achieved with rabbit monoclonal antibodies designed and developed
using IPA’s proprietary B Cell Select® platform for the
clinical-stage company, OncoResponse Inc. This achievement
underscores IPA’s leadership as a Contract Research Organization
creating high-quality therapeutic antibodies, while pioneering work
in the field of rabbit monoclonal antibody development. These
antibodies are rapidly gaining recognition as a unique tool in
therapies due to their distinctive properties, advancing into
clinical trials aimed at improving patient outcomes.
OncoResponse’s Breakthrough in Cancer Treatment
In a live presentation at the recent PEGS 2024 conference,
OncoResponse shared exciting updates on two novel antibodies, OR502
and OR641, both of which were discovered and refined using IPA’s
innovative B Cell Select® platform:
- OR502, a novel, humanized anti-leukocyte immunoglobulin like
receptor B2 (LILRB2) antibody, has successfully entered Phase I/II
clinical trials, showing excellent safety profile, and is being
evaluated for efficacy in treating advanced solid tumors.
Preclinical models have demonstrated that OR502 is a best-in-class
anti-LILRB2 antibody that reverses immunosuppression caused by
myeloid cells in the TME.
- OR641, a novel, humanized dual antagonist antibody targeting
both LILRB1 and LILRB2, has completed Cell Line Development and is
undergoing IND-enabling studies. Preclinical models have
demonstrated its superior ability to reverse immunosuppression
caused by myeloid and lymphoid cells compared to other
anti-LILRB1/2 antibodies.
Driving Antibody Discovery and Design for Clinical
Success
IPA’s proprietary B Cell Select® platform has been instrumental
in the rapid design and discovery of antibodies that have advanced
to clinical stages for numerous clients. By preserving the natural
structure of antibodies, IPA’s technology supports optimal
functioning of the therapies in a clinical setting. Through
comprehensive testing and validation, the process ensures that
these antibodies maintain their efficacy and reliability from the
lab to the clinic.
"At ImmunoPrecise Antibodies, our mission is not just to develop
antibodies, but to redefine what’s possible in therapeutic
interventions," said Dr. Jennifer Bath, President and CEO of IPA.
"Our innovative platform, built on years of expertise, has
consistently delivered antibodies with superior qualities, many of
which are now advancing in clinical trials. This reflects our
unwavering commitment to innovation and our strategic advantage in
the market. We are proud to support our clients in bringing
groundbreaking, life-changing treatments to patients around the
world, reinforcing the long-term value of our technologies."
Harnessing Rabbit B Cell Technology for Breakthrough Antibody
Discovery
The Rabbit B Cell platform, a rapidly advancing technology in
therapeutic antibody development, played a pivotal role in the
discovery process. This platform excels at generating high-affinity
and highly specific rabbit monoclonal antibodies, a demand met with
very limited providers in the market.
IPA has successfully utilized their B Cell Select platform in
over 200 antibody programs, achieving remarkable success against a
variety of targets, including small molecules, peptides, and
proteins. The distinctive properties of rabbit antibodies, combined
with IPA’s expertise, have consistently led to the development of
promising therapeutic candidates. Building on this success, IPA is
now offering more complex therapeutic rabbit antibody campaigns as
a partnering model, providing companies with greater flexibility in
structuring their more complicated programs.
Outlook
The field of rabbit monoclonal antibody (mAb) therapeutics is
advancing rapidly, driven by innovations in antibody engineering
and humanization techniques. These advancements are making rabbit
mAbs increasingly popular for human therapeutic use. The unique
properties of rabbit antibodies, combined with IPA’s full-service
technologies, such as in silico humanization, indicate a strong
potential for more rabbit-derived mAbs to enter clinical trials and
achieve approval in the coming years. The distinctive advantages of
rabbit antibodies make them a promising foundation for future
therapeutic development. As this technology progresses, IPA remains
at the forefront, harnessing these innovations to bring new,
effective treatments to the clinic, reinforcing our growing
leadership in the industry.
Dr. Kamal D. Puri, Chief Scientific Officer of OncoResponse,
recognized IPA’s pivotal role in their success, praising the
quality and reliability of IPA’s antibody discovery services. “We
are thrilled to have worked with IPA to discover our lead
therapeutic antibodies. The IPA team’s deep experience and know-how
with a battery of customized, high-throughput discovery strategies
has played a critical role in the successful discovery of our
molecules with unsurpassed speed and efficiency,” said Kamal D.
Puri, Chief Scientific Officer of OncoResponse.
About OR502
LILRB2 is an immunoinhibitory receptor expressed on
tumor-associated macrophages (TAMs) found in the tumor
microenvironment (TME). TAMs inhibit the activity of checkpoint
inhibitor (CPI) therapy and prevent T cells from killing tumors.
Blocking the inhibitory activity of TAMs and promoting the activity
of tumor-killing T cells reverses inhibition of CPI therapy,
potentially leading to more and deeper responses to CPIs in
patients. This is the mechanism of OR502, which modulates LILRB2 by
blocking its engagement of HLA-G on tumor cells and prevents the
suppression of the myeloid cells. Elevated expression of LILRB2
correlates with reduced patient survival in various tumor types.
This humanized monoclonal antibody, OR502, targets LILRB2 and
blocks the inhibitory activity of TAMs and promotes the activity of
tumor-killing T cells, reversing inhibition of CPI therapy.
About OncoResponse
OncoResponse is a clinical-stage, immuno-oncology biotech
company developing cancer immunotherapies using clues from the
immune systems of Elite Cancer Responders. In a broad strategic
alliance with MD Anderson Cancer Center, OncoResponse deploys a
proprietary B-cell discovery platform to identify and develop novel
antibodies targeting immune cells in the tumor microenvironment.
The company’s lead clinical candidate, OR502 is a best-in-class
anti-LILRB2 antibody that rescues innate and adaptive immune
responses from LILRB2-mediated immune suppression and has entered
clinical study in 2023. OR502 clinical studies are being conducted
with support from the Cancer Prevention Research Institute of Texas
(CPRIT) DP230076. Additional pipeline candidates that modulate
suppressive macrophage activity are under development, including
OR641, a unique dual anti-LILRB2/1 antagonist antibody that
promotes a Th1-like immune response. For more information, please
visit www.oncoresponse.com and follow us on LinkedIn and X.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company
that leverages multi-omics modeling and complex artificial
intelligence through a series proprietary and patented
technologies. The Company owns an integrated end-to-end suite of
capabilities to support the development of therapeutic antibodies
and are known for solving very complex industry challenges. IPA has
several subsidiaries in North America and Europe including entities
such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise
Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V.
(collectively, the “IPA Family”).
Forward-Looking Statement
This news release contains forward-looking statements within the
meaning of applicable United States securities laws and Canadian
securities laws. Forward-looking statements are often identified by
the use of words such as “potential”, “plans”, “expects” or “does
not expect”, “is expected”, “estimates”, “intends”, “anticipates”
or “does not anticipate”, or “believes”, or variations of such
words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. Forward-looking information contained in this news
release includes, but is not limited to, statements relating to the
expected outcome on the market, the life sciences, drug discovery
and development, and clinical readiness or effectiveness of
IPA-discovered therapeutics. In respect of the forward-looking
information contained herein, IPA has provided such statements and
information in reliance on certain assumptions that management
believed to be reasonable at the time, those assumptions include:
the continued successful of IPA’s technology in discovering and
developing antibodies, timely regulatory approval and acceptance of
therapies developed using the Company’s technologies, the potential
for partnerships in antibody discovery and development; and the
expectation that these technological advancements will drive
increased revenue streams and sustained financial growth for the
Company.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, as discussed in the Company’s
Annual Report on Form 20-F for the year ended April 30, 2024 (which
may be viewed on the Company’s SEDAR+ profile at www.sedarplus.ca
and EDGAR profile at www.sec.gov/edgar). Should one or more of
these risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. Accordingly, readers should not
place undue reliance on forward-looking statements contained in
this news release. The forward-looking statements contained in this
news release are made as of the date of this release and,
accordingly, are subject to change after such date. The Company
does not assume any obligation to update or revise any
forward-looking statements, whether written or oral, that may be
made from time to time by us or on our behalf, except as required
by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240926217701/en/
Investor Relations Contact Kirsten Beduya Quantum Media
Group, LLC kirsten@quantum-corp.com
Grafico Azioni ImmunoPrecise Antibodies (NASDAQ:IPA)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni ImmunoPrecise Antibodies (NASDAQ:IPA)
Storico
Da Gen 2024 a Gen 2025
